- 180 Life Sciences, a clinical stage research company, went public last November.
- The company brings together six scientists famous for their work in anti-inflammatory research.
- They have several projects underway, one of which uses cannabinoids to treat arthritis and chronic pain.
- The company has proceeds from Direct Offerings and Private Placement.
- The company’s stock price has increased 182% in 3 months and should be watched for a potential 43% profit.
For further details see:
180 Life Sciences Continues Uptrend With Cannabinoid And Anti-Inflammatory Research